Gracell stock surges ~30% on FDA nod to start trial of blood cancer drug

Feb. 03, 2023 8:24 AM ETGracell Biotechnologies Inc. (GRCL)By: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)


  • Gracell Biotechnologies (NASDAQ:GRCL) said that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to start a trial of blood cancer drug GC012F.
  • The Chinese company plans to begin a phase 1b/2 trial

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.